Clinical trials: Sickle Cell Disorder
Sickle Cell Disease, Sickle Cell Anemia
A Study of HQK-1001 in Patients With Sickle Cell Disease
The purpose of this study is to evaluate the safety and tolerability of three dose levels of HQK-1001 administered once daily for 26 weeks in subjects with sickle cell disease.
- Conditions
- Sickle Cell Disease, Sickle Cell Anemia, Sickle Cell Disorders, Hemoglobin S Disease
- Trial name
- NCT01322269
- Testing
- HQK-1001
- Where
- 16 sites in United States, Canada and 3 more
- Volunteers
- 52 people
- Sponsor
- HemaQuest Pharmaceuticals Inc.
Anemia, Sickle Cell
Telemedicine for Children With Sickle Cell Disease
The purpose of this study is to learn more about how the use of two different types of telemedicine (distance medical care) can address barriers to receiving comprehensive sickle cell care, and whether care can be improved.
- Trial name
- NCT05087303
- Testing
- Types of Telemedicine Delivery Models
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Indiana University
Sickle Cell Disease
Drug Interaction Study of GBT440 With Caffeine, S-warfarin, Omeprazole, and Midazolam in Healthy Subjects
The purpose of this study to evaluate the effect of concomitant administration of GBT440 on caffeine (a CYP1A2 probe substrate), S warfarin (a CYP2C9 probe substrate), omeprazole (a CYP2C19 probe substrate), and midazolam (a…
- Trial name
- NCT02567682
- Testing
- GBT440
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Global Blood Therapeutics
Anemia, Sickle Cell
Dipyridamole/Magnesium To Improve Sickle Cell Hydration
The purpose of this study is to determine the benefits as well as side effects of giving drugs called dipyridamole and magnesium to patients with sickle cell anemia (SCA).
- Trial name
- NCT00276146
- Testing
- oral dipyridamole, oral magnesium, or a combination of both
- Where
- 3 sites in United States
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Sickle Cell Disease
Curative Versus Disease-Modifying Therapies in Children With Severe Sickle Cell Disease
The research proposed is a pilot study of pediatric and adolescent/young adult patients who have received the curative intervention (MSD-SCT), disease-modifying interventions (HU or CT) or SCC (control), with respect to three…
- Trial name
- SCD_Cross (NCT01369160)
- Testing
- Quality of Life measures
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- Emory University
Sickle Cell Disease, Sickle Cell Crisis
Ketorolac for Acute Vaso-Occlusive Crisis in Pediatric Sickle Cell Disease
Pediatric patients who present with acute vaso-occlusive pain crisis may have equivalent pain reduction scores at lower dosing of intravenous Ketorolac compared to standard dosing of 0.5 mg/kg/dose IV (<16yo max 15mg, >16yo max…
- Conditions
- Sickle Cell Disease, Sickle Cell Crisis, Veno-occlusive Disease
- Trial name
- NCT06579703
- Testing
- Ketorolac
- Volunteers
- 102 people
- Sponsor
- Children's Blood and Cancer Center at Dell Children's Medical Center
Sickle Cell Disease
Evaluation of Different Dose Regimens of Aes-103 Given for 28 Days to Subjects With Stable Sickle Cell Disease
Sickle cell disease (SCD) is a genetic blood disorder characterized by the presence of sickle-shaped red blood cells. In the U.S. and the U.K. this occurs primarily in persons of African origin.
- Trial name
- NCT01987908
- Testing
- Aes-103
- Where
- United Kingdom
- Volunteers
- 35 people
- Sponsor
- Baxalta now part of Shire
Sickle Cell Anemia, Sickle Cell Disease
Heart Arteries and Sickle Cell Disease / Coeur Artères DREpanocytose
The CADRE study is a multinational observational cohort of patients with sickle-cell disease (SCD) in five west and central sub-Saharan African countries.
- Trial name
- CADRE (NCT03114137)
- Where
- 13 sites in Cameroon, Côte d’Ivoire and 4 more
- Volunteers
- 4,500 people, healthy volunteers welcome
- Sponsor
- Cardiologie et Développement
Sickle Cells Disease
RH Genotype Matched RBC Transfusions
To determine the feasibility and efficacy of matching donor red cells by RH genotype for a cohort of chronically transfused patients with SCD.
- Trial name
- RBC (NCT04156893)
- Testing
- Red cell units that are genotype matched at the RHD and RHCE loci
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Children's Hospital of Philadelphia
Sickle Cell Disease
Disseminating NIH Evidence Based Sickle Cell Recommendations in North Carolina
This project will improve the efficiency and quality of healthcare for persons with sickle cell disease, an under-served and at risk population by implementing a co-management model of care.
- Trial name
- NCT03253211
- Where
- United States
- Volunteers
- 4,392 people
- Sponsor
- Duke University
Sickle Cell Disease
Assessment of Opioid Analgesia in Sickle Cell
To develop and validate a non-invasive, in vivo, phenotyping method for CYP2D6 using the non-injurious neuroselective electrical stimulation technique: pain perception threshold/pain tolerance threshold (PPT/PTT) in children and…
- Trial name
- NCT00513864
- Testing
- Dextromethorphan, Codeine, Morphine
- Where
- United States
- Sponsor
- Children's National Research Institute
Sickle Cell Disease and Pregnancy
HEMAGO Monitoring and Impact on the Occurrence of Complications During Pregnancy in Sickle Cell Patients
Sickle cell disease is the most common monosemic genetic disease in the world and affects approximately 32,000 people in France.
- Trial name
- HEMAGO (NCT06620887)
- Testing
- Evaluate the impact of HEMAGO program on maternal morbidity and mortality in sickle cell disease patients during their pregnancies.
- Where
- 3 sites in France
- Volunteers
- 100 people
- Sponsor
- Hospices Civils de Lyon
Sickle Cell Anemia
Transcranial Doppler (TCD) With Transfusions Changing to Hydroxyurea
The primary goal of the Phase III TWiTCH trial is to compare 24 months of alternative therapy (hydroxyurea) to standard therapy (transfusions) for pediatric subjects with sickle cell anemia and abnormally high (≥200 cm/sec)…
- Trial name
- TWiTCH (NCT01425307)
- Testing
- Hydroxyurea
- Volunteers
- 159 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Sickle Cell Anemia
Effect of Exercise With and Without HMB on Body Composition and Muscle Strength in Sickle Cell Anaemia
Wasting is a common and significant problem in sickle cell anaemia (SCA) that correlates with poorer clinical outcome such as frequent painful crises, acute chest syndrome and sub normal resistance to infection.
- Trial name
- NCT04001907
- Testing
- Resistance exercise, β-hydroxy-β-methylbutyrate
- Volunteers
- 24 people
- Sponsor
- The University of The West Indies
Sickle Cell Disease, Hemoglobin SC
Bone Marrow Transplantation, Hemoglobinopathies, SCALLOP
Patients are being asked to participate in this study because they have severe sickle cell anemia (SCD) with or without the beta thalassemia trait.
- Trial name
- SCALLOP (NCT00578344)
- Testing
- Busulfan, Campath 1H, Cyclophosphamide and MESNA
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Tami D. John
Chronic Leg Ulcer, Sickle Cell Disease
Autologous Bone Marrow Stem Cells for Chronic Leg Ulcer Treatment in Sickle Cell Disease
The purpose of this study is to evaluate the safety and efficacy of autologous bone marrow stem cell implantation for the treatment of leg ulcer in adult patients with sickle cell disease.
- Trial name
- NCT02619734
- Testing
- Infusion of Autologous Bone Marrow Mononuclear Cells
- Volunteers
- 40 people
- Sponsor
- Federal University of Bahia
Sickle Cell Disease
Mesenchymal Stromal Cells for Haplo Hematopoietic Cell Transplantation for Sickle Cell Disease
This trial is being conducted as a step toward testing the long-term hypothesis that freshly cultured, autologous mesenchymal stromal cells (MSCs) grown in platelet lysate-containing medium will modulate recipient T-cell immune…
- Trial name
- NCT03298399
- Testing
- Autologous MSCs
- Sponsor
- Emory University
Sickle Cell Anemia, Beta Thalassemia
Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia
Background: Sickle cell disease (SCD) is an inherited disorder of the blood. It can damage a person s organs and cause serious illness and death. A blood stem cell transplant is the only potential cure for SCD.
- Trial name
- NCT05357482
- Testing
- TBI, Hydroxyurea, briquilimab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Sickle Cell Disease
Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease
The goal of this observational study is to help us understand more about the best ways to help individuals living with Sickle Cell Disease (SCD) get the best care.
- Trial name
- RECIPE (NCT06385886)
- Testing
- Linkage Coordinator
- Where
- 9 sites in United States
- Volunteers
- 500 people
- Sponsor
- RTI International
Sickle Cell Disease
A Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease
The purpose of this study was to evaluate the safety and tolerability, and the pharmacokinetic and biologic activity of INCB059872 in participants with sickle cell disease.
- Trial name
- NCT03132324
- Testing
- INCB059872
- Where
- 7 sites in United States
- Volunteers
- 12 people
- Sponsor
- Incyte Corporation